.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE02_Panitumumab.Panitumumab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FE02_Panitumumab.Panitumumab| name: | Panitumumab |
| ATC code: | L01FE02 | route: | intravenous |
| n-compartments | 2 |
Panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (EGFR). It is primarily used for the treatment of metastatic colorectal cancer, especially in patients with wild-type KRAS status. It is approved for medical use and is administered via intravenous infusion.
Pharmacokinetic parameters reported in adult cancer patients (metastatic colorectal cancer), generally similar across sexes. Values are based on population pharmacokinetic analyses.
Doi, T, et al., & Ohtsu, T (2009). Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors. International journal of clinical oncology 14(4) 307–314. DOI:10.1007/s10147-008-0855-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19705240
Krens, LL, et al., & Gelderblom, H (2014). Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer chemotherapy and pharmacology 73(2) 429–433. DOI:10.1007/s00280-013-2353-0 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24258455
Yang, BB, et al., & Pérez Ruixo, JJ (2010). Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clinical pharmacokinetics 49(11) 729–740. DOI:10.2165/11535970-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/20923247